Clinical trial: The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 1, 2009, Pages 104-114

  Agrawal, A ^a   Houghton, L A ^a,b   Morris, J ^b   Reilly, B ^b   Guyonnet, D ^c   Goupil Feuillerat, N ^c   Schlumberger, A ^c   Jakob, S ^c   Whorwell, P J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c DANONE RESEARCH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LACTIS DN 173 010; BLOATING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FERMENTED PRODUCT; GASTROINTESTINAL TRANSIT; HUMAN; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS BULGARICUS; MILK; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS THERMOPHILUS;

ADULT; AGED; ANALYSIS OF VARIANCE; BIFIDOBACTERIUM; CONSTIPATION; CULTURED MILK PRODUCTS; DILATATION, PATHOLOGIC; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PROBIOTICS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57649208538     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03853.x     Document Type: Article

References (56)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller R. Functional bowel disorders. Gastroenterology 2006 130 : 1480 91.
2. Drossman DA, Li Z, Andruzzi E, et al. US House-holder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993 38 : 1569 80.
3. Thompson WG. A world view of IBS. In : Spiller R, Camilleri M eds. The Irritable Bowel Syndrome, Diagnosis and treatment. Edinburgh : WB Saunders, 2002 : 17 26.
4. Longstreth GF. Definition and classification of IBS: current consensus and controversies. Gastroenterol Clin North Am 2005 34 : 173 87.
5. Longstreth GF, Bolus R, Naliboff B, et al. Impact of irritable bowel syndrome on patient lives: development and psychometric documentation of disease-specific measure for use in clinical trials. Eur J Gastroenterol Hepatol 2005 17 : 411 20.
6. Wilson A, Longstreth G, Knight K, et al. Quality of life in managed care patients with irritable bowel syndrome. Manag Care Interface 2004 17 : 24 8.
7. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007 56 : 1770 98.
8. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel syndrome. Br Med J 1978 2 : 653 4.
9. Maxton DG, Morris JA, Whorwell PJ. Ranking of symptoms by patients with irritable bowel syndrome. Br Med J 1989 299 : 1138.
10. Schmulson M, Lee O-Y, Chang L, Naliboff B, Mayer EA. Symptom difference in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999 94 : 2929 35.
11. Lee O-Y, Mayer EA, Schmulson M, Chang L, Naliboff B. Gender-related differences in IBS symptoms. Am J Gastroenterol 2001 96 : 2184 93.
12. Chang L, Lee O-Y, Naliboff B, Schmulson M, Mayer EA. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol 2001 96 : 3341 7.
13. Hungin APS, Whorwell PJ, Tack J, Mearins F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003 17 : 643 50.
14. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhoea in the United States. Prevalence and impact. Dig Dis Sci 2000 45 : 1166 71.
15. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacey BE, Olden RW, Cromwell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation and diarrhoea. Am J Gastroenterol 2003 98 : 2454 9.
16. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999 94 : 1320 6.
17. Maxton DG, Whorwell PJ. Abdominal distension in irritable bowel syndrome: the patients' perspective. Eur J Gastroenterol Hepatol 1992 4 : 241 3.
18. Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distension in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006 131 : 1003 10.
19. Agrawal A, Whorwell PJ, Houghton LA. Is abdominal distension related to delayed small and large bowel transit in patients with constipation predominant irritable bowel syndrome. Gastroenterology 2006 130 (No 4, Suppl. 2) A93, 632.
20. O'Leary C, Quigley EMM. Small bowel bacterial overgrowth, celiac disease and IBS: what are the associations? Am J Gastroenterol 2003 98 : 720 2.
21. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal micobial population in the irritable bowel syndrome. Microbiologica 1982 5 : 185 94.
22. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005 100 : 373 82.
23. Matto J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005 43 : 213 22.
24. Maukonen J, Satokari R, Matto J, Soderlund H, Matilla-Sandholm T, Saarela M. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006 55 : 625 33.
25. Pimentel M, Chow EJ, Lin HC. Normalisation of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo controlled study. Am J Gastroenterol 2003 98 : 412 9.
26. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 2003 48 : 86 92.
27. Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Gastroenterol 2006 6 : G1089 95.
28. Verdu EF, Bercik P, Bergonzelli GE, et al. Lactobacillus paracasei normalizes muscle hyperconstractility in murine model of postintective gut dysfunction. Gastroenterology 2004 127 : 826 37.
29. Massi V, Ioan P, Budriesi R, et al. The effects of probiotic bacteria on spontaneous contraction of isolated guinea pig intestine. Gastroenterology 2004 126 (No 4, Suppl. 2 A-517, T1813.
30. Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomised, controlled study. Aliment Pharmacol Ther 2002 16 : 587 93.
31. Meance S, Cayuela C, Raimondi A, et al. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 2003 15 : 15 22.
32. Bouvier M, Meance S, Bouley C, et al. Effects of consumptionn of a milk fermented by the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans. Bioscience Microflora 2001 20 : 43 8.
33. Meance S, Cayuela C, Turchet P, et al. A fermented milk with a bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microb Ecol Health Dis 2001 13 : 217 22.
34. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005 17 : 687 96.
35. Quigley EM, Plourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007 19 : 166 72.
36. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastroinestinal microbiota in irriable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008 103 : 1557 67.
37. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomised, double-blind, controlled trial. Aliment Pharmacol Ther 2007 26 : 475 86.
38. Drossman DA, Camilleri M, Mayer EA. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
39. Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002 50 : 471 4.
40. Wald A, Van Theil DH, Hoechstetter L, et al. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981 80 : 1497 500.
41. Lewis MJV, Houghton LA, Whorwell PJ. Abdominal distension in females with irritable bowel syndrome: the effect of the menopause and hormone replacement therapy. Gut 2001 48 (Suppl. 1 A46, 168.
42. Lewis M, Reilly B, Houghton LA, Whorwell PJ. Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut 2001 48 : 216 20.
43. Reilly B, Bolton M, Houghton LA, Lewis M, Whorwell PJ. A device for 24 hour ambulatory monitoring of abdominal girth using inductive plethysmography. Physiol Meas 2002 23 : 661 70.
44. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology 1987 92 : 40 7.
45. Levitt MD. Production and excretion of hydrogen gas in man. N Engl J Med 1969 281 : 122 7.
46. Delgado-Aros S, Camilleri M, Garcia MA, Burton D, Busciglio I. High body mass alters colonic sensory-motor function and transit in humans. Am J Physiol (Gastrointestinal Liver Physiol) 2008 295 : G382 8.
47. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol 2003 38 : 36 42.
48. Madsen JL, Graff J. Effects of ageing on gastrointestinal motor function. Age Ageing 2004 33 : 154 9.
49. Woodmansey EJ. Intestinal bacteria and ageing. J Appl Microbiol 2007 102 : 1178 86.
50. Heaton KW, Ghosh S, Braddon FEM. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991 32 : 73 9.
51. Houghton LA, Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005 17 : 500 11.
52. Agrawal A, Houghton LA, Lea R, Reilly B, Whorwell PJ. Abdominal bloating and distension in irritable bowel syndrome: a role for visceral sensation. Gastroenterology 2008 134 : 1882 9.
53. Spiller RC. Irritable bowel syndrome: bacteria and inflammation - clinical relevance now. Curr Treat Options Gastroenterol 2007 10 : 312 21.
54. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom response and relationship to cytokine profiles. Gastroenterology 2005 128 : 541 51.
55. Kamiya T, Wang L, Forsythe P, et al. Inhibitory effects of Lactobacillus reuteri on visceral pain indiced by colorectal distension in Sprague-Dewley rats. Gut 2008 55 : 191 6.
56. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006 101 : 1581 90.